Neukio Biotherapeutics on a New Mission
Quality-based
Specification-oriented
Patient-centered
Building new future in cell therapy
About Neukio
Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.
Allogenic
Scalability
Solid tumors
indications
Why iPSC-CAR-NK?
1. NK cells can be universal and readily available (allogeneic use)
2. NK cells can be manufactured in scale via iPSC differentiation and banking
3. Engineered NK have potential to eradicate solid tumors
Gene Editing
NK Diff. & Exp.
DP
Banking
iPSC Bank
News
Press Releases
-442.jpg)
About Founder
Richard Liqun Wang Ph. D., MBA.
Founder, Chairman and CEO， Neukio Biotherapeutics
Former positions held：
- VP & CTO, Fosun Pharma, and founding CEO, Fosun Kite Biotech
- COO, Cellular Biomedical Group (CBMG)
- Head of Operations, GSK R&D Center in China
- Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
- Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
- Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
WELCOME ABOARD
